In an investor presentation for the 43rd Annual J.P. Morgan Healthcare Conference, Evolent Health (EVH) said it is reiterating its long-term outlook, including that it is maintain prior 15%-plus annual revenue outlook. The company also said its FY25 outlook will be disclosed on February 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $17 from $20 at RBC Capital
- Evolent Health to Present at J.P. Morgan Conference
- Evolent Health price target lowered to $20 from $24 at Truist
- Evolent Health price target lowered to $18 from $21 at Citi
- Evolent Health price target lowered to $18 from $27 at JMP Securities